An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)

T. J. Smith; P. J. Coyne; P. S. Staats; T. Deer; L. J. Stearns; R. L. Rauck; R. L. Boortz-Marx; E. Buchser; E. Català; D. A. Bryce; M. Cousins; G. E. Pool; Implantable Drug Delivery Systems Study Group

doi:10.1093/annonc/mdi156

$An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)$

Journal article

Open access

Peer reviewed

An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)

T. J. Smith, P. J. Coyne, P. S. Staats, T. Deer, L. J. Stearns, R. L. Rauck, R. L. Boortz-Marx, E. Buchser, E. Català, D. A. Bryce, …

Annals of oncology, Vol.16(5), pp.825-833

05/2005

DOI: 10.1093/annonc/mdi156

PMID: 15817596

Files and links (1)

url

https://doi.org/10.1093/annonc/mdi156View

Published (Version of record) Open Access

Abstract

Background:: The randomized clinical trial of implantable drug delivery systems (IDDS) plus comprehensive medical management (CMM) versus CMM alone showed better clinical success at 4 weeks for IDDS patients. This ‘as treated’ analysis assessed if improvements in pain control, drug toxicity and survival were maintained over time. Patients and methods:: We compared those who received IDDS with those who did not receive IDDS (non-IDDS). All patients had Visual Analogue Scores (VAS) for pain ≥5/10 on at least 200 mg morphine or equivalent daily. Results:: At 4 weeks, 46 of 52 (88.5%) IDDS patients achieved clinical success compared with 65 of 91 (71.4%; P=0.02) non-IDDS patients, and more often achieved ≥20% reduction in both pain VAS and toxicity [35 of 52 (67.3%) versus 33 of 91 patients (36.3%); P=0.0003]. By 12 weeks, 47 of 57 (82.5%) IDDS patients had clinical success compared with 35 of 45 (77.8%; P=0.55) non-IDDS patients, and more often had a ≥20% reduction in both pain VAS and toxicity [33 of 57 (57.9%) versus 15 of 45 patients (33.3%); P=0.01]. At 12 weeks the IDDS VAS pain scores decreased from 7.81 to 3.89 (47% reduction) compared with 7.21 to 4.53 for non-IDDS patients (42% reduction; P=0.23). The 12 week drug toxicity scores for IDDS patients decreased from 6.68 to 2.30 (66% reduction), and for non-IDDS patients from 6.73 to 4.13 (37% reduction; P=0.01). All individual drug toxicities improved with IDDS at both 4 and 12 weeks. At 6 months, only 32% of the group randomized to CMM and who did not cross over to IDDS were alive, compared with 52%–59% for patients in those groups who received IDDS. Conclusions:: IDDS improved clinical success, reduced pain scores, relieved most toxicity of pain control drugs, and was associated with increased survival for the duration of this 6 month trial.

Pain

cancer

implantable devices

intraspinal therapy

intrathecal therapy

opioids

Details

Title: Subtitle: An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)
Creators: T. J. Smith - Virginia Commonwealth University
P. J. Coyne - Virginia Commonwealth University
P. S. Staats - Virginia Commonwealth University
T. Deer - Virginia Commonwealth University
L. J. Stearns - Virginia Commonwealth University
R. L. Rauck - Virginia Commonwealth University
R. L. Boortz-Marx - Virginia Commonwealth University
E. Buchser - Virginia Commonwealth University
E. Català - Virginia Commonwealth University
D. A. Bryce - Virginia Commonwealth University
M. Cousins - Virginia Commonwealth University
G. E. Pool - Virginia Commonwealth University
Implantable Drug Delivery Systems Study Group
Contributors: P Hitchon (Contributor) - University of Iowa, Neurosurgery
Resource Type: Journal article
Publication Details: Annals of oncology, Vol.16(5), pp.825-833
DOI: 10.1093/annonc/mdi156
PMID: 15817596
NLM abbreviation: Ann Oncol
ISSN: 0923-7534
eISSN: 1569-8041
Publisher: Oxford University Press
Language: English
Date published: 05/2005
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Neurosurgery
Record Identifier: 9984304030802771

Metrics

18 Record Views

122 Times Cited - Web of Science